帶狀皰疹治療市場規模、佔有率和成長分析（按診斷、治療/預防、給藥途徑、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球帶狀皰疹治療市場規模將達到 24.2 億美元，到 2025 年將達到 26.6 億美元，到 2033 年將達到 57.1 億美元，預測期（2026-2033 年）的複合年成長率為 10%。

全球帶狀皰疹治療市場正經歷強勁成長，主要促進因素是帶狀皰疹發病率的上升，尤其是在老年人群中。人們對預防措施和帶狀皰疹後遺症神經痛管理的認知不斷提高，推動了對疫苗和抗病毒治療的需求。人工智慧等創新技術在研發領域的應用，正在簡化藥物發現流程，並改善病患的治療效果。臨床試驗和疫苗研發的重點在於增強長期免疫力並降低復發率。此外，新興市場正利用其醫療保健服務的改善和公共疫苗接種政策的優勢。儘管目前在研療法有限，且由於老齡化相關的顧慮和缺乏全民疫苗接種計劃，疫苗接受度存在差異，但人口老齡化和重組帶狀皰疹疫苗的有效性，仍展現出良好的市場前景。

推動全球帶狀皰疹治療市場發展的因素

全球帶狀皰疹治療市場的發展主要得益於人工智慧 (AI) 對藥物研發過程的變革性影響。先進的演算法能夠分析大量資料集，包括基因組、蛋白質組和化合物庫，從而幫助識別有前景的抗病毒候選藥物。這項技術創新可以顯著降低臨床前和臨床開發階段的成本和時間。因此，許多製藥公司和生技Start-Ups公司正在採用人工智慧平台來加強其研究活動，加速開發用於治療帶狀皰疹及其併發症（例如帶狀皰疹後遺症神經痛(PHN)）的新一代疫苗和治療方法。

限制全球帶狀皰疹治療市場的因素

人工智慧在帶狀皰疹治療市場的應用面臨著許多挑戰，其中最主要的障礙在於嚴格的法規結構和資料隱私問題，尤其是在演算法開發中如何使用患者資訊。一些地區醫療資料保護法律尤其嚴格，這往往會阻礙人工智慧在臨床實踐中的應用，進而可能減緩創新技術的整體普及速度。這些監管方面的挑戰阻礙了人工智慧解決方案在該領域的快速發展，最終限制了市場擴張和最先進治療方法的潛在益處。

全球帶狀皰疹治療市場趨勢

全球帶狀皰疹治療市場正呈現出一個顯著的趨勢，即整合個人化人工智慧模型以預防帶狀皰疹後遺症神經痛（PHN）。這些進展利用患者特異性數據，例如免疫反應、遺傳易感性和疼痛閾值，來制定量身定做的治療通訊協定，從而提高療效。製藥公司正致力於透過人工智慧分析真實世界的臨床數據來最佳化藥物劑量和改善治療途徑，這不僅將改善患者預後，還將推動市場成長。這種創新方法有望徹底改變帶狀皰疹及其併發症的治療方式，並代表治療領域正在發生的變革。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 一手和二手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球帶狀皰疹治療市場規模（按診斷和複合年成長率分類）（2026-2033 年）

• 檢查室檢測
• 螢光顯微鏡
• 即時聚合酵素鏈鎖反應（PCR）
• 血清學檢測
• 其他

全球帶狀皰疹治療市場規模：治療與預防及複合年成長率（2026-2033）

• 抗病毒藥物
• 麻醉性止痛藥
• 抗發炎藥
• 抗組織胺藥
• 抗驚厥藥
• 辣椒素
• 麻醉膏、凝膠或貼片
• 疫苗
• 其他

全球帶狀皰疹治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 外用藥物
• 其他

全球帶狀皰疹治療市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院診所
• 診斷中心
• 研究和學術機構
• 居家醫療環境
• 其他

全球帶狀皰疹治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

  主要企業簡介

  • 葛蘭素史克（GSK）（英國）
  • 默克公司（美國）
  • 輝瑞公司（美國）
  • 賽諾菲（法國）
  • 諾華公司（瑞士）
  • 安斯泰來製藥株式會社（日本）
  • ModernaTX公司（美國）
  • Dynavax Technologies Corporation（美國）
  • Curevo公司（美國）
  • 江蘇瑞克生物科技有限公司（中國）
  • 綠竹生物科技有限公司 (中國)
  • 韓國綠十字公司
  • BioNTech（德國）
  • 百時美施貴寶（美國）
  • 武田藥品工業株式會社（日本）
  • SK生物科學（韓國）
  • Vaxine Pty Ltd（澳洲）
  • EpiVax（美國）
  • Virios Therapeutics（美國）
  • WEX製藥公司（加拿大）

結論與建議

Global Herpes Zoster Therapeutics Market size was valued at USD 2.42 Billion in 2024 and is poised to grow from USD 2.66 Billion in 2025 to USD 5.71 Billion by 2033, growing at a CAGR of 10% during the forecast period (2026-2033).

The global herpes zoster therapeutics market is witnessing robust growth, largely fueled by the increasing incidence of shingles, particularly in older adults. Heightened awareness regarding preventive measures and management of post-herpetic neuralgia is driving the demand for vaccines and antiviral treatments. Innovations like AI in research are streamlining drug discovery and enhancing patient outcomes. The rise in clinical trials and vaccine development is focusing on improving long-term immunity and reducing recurrence rates. Additionally, emerging markets are capitalizing on improved healthcare access and public vaccination initiatives. Despite the limited number of therapeutic agents in development and inconsistent vaccine acceptance due to factors like age-related fears and lack of universal vaccination programs, the aging population and the effectiveness of recombinant zoster vaccines indicate a promising market outlook.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Herpes Zoster Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Herpes Zoster Therapeutics Market Segments Analysis

Global Herpes Zoster Therapeutics Market is segmented by Diagnosis, Treatment and Prevention, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing and Others. Based on Treatment and Prevention, the market is segmented into Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines and Others. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is being driven by the transformative impact of Artificial Intelligence on drug discovery processes. Advanced algorithms are capable of analyzing vast datasets, encompassing genetic, proteomic, and chemical compound libraries, which facilitates the identification of promising antiviral candidates. This technological innovation significantly minimizes both costs and time linked with preclinical and clinical development phases. As a result, numerous pharmaceutical companies and biotech startups are employing AI-powered platforms to enhance their research efforts, thereby accelerating the creation of next-generation vaccines and therapies aimed at treating shingles and its associated complications, such as post-herpetic neuralgia (PHN).

Restraints in the Global Herpes Zoster Therapeutics Market

The advancement of AI in the herpes zoster therapeutics market faces significant obstacles due to stringent regulatory frameworks and concerns surrounding data privacy, particularly regarding the use of patient information for algorithm development. In regions where health data protection laws are particularly rigorous, the integration of AI in clinical settings is often impeded, which can slow down the overall deployment of innovative technologies. These regulatory challenges may create barriers to the rapid progression of AI-driven solutions in this field, ultimately restricting market expansion and the potential benefits of cutting-edge therapeutic approaches.

Market Trends of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is increasingly witnessing a trend towards the integration of personalized AI models aimed at preventing post-herpetic neuralgia (PHN). These advancements leverage patient-specific data, including immune responses, genetic predispositions, and pain thresholds, to craft tailored treatment protocols that enhance therapeutic efficacy. By utilizing AI to analyze real-world data, pharmaceutical companies are focusing on optimizing medication dosages and treatment pathways, which not only improve patient outcomes but also drive market growth. This innovative approach promises to revolutionize the management of herpes zoster and its complications, reflecting an evolving landscape in the therapeutic domain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Herpes Zoster Therapeutics Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Laboratory Testing
• Immunofluorescent Microscopy
• Real-Time Polymerase Chain Reaction (PCR)
• Serological Testing
• Others

Global Herpes Zoster Therapeutics Market Size by Treatment and Prevention & CAGR (2026-2033)

• Market Overview
• Antiviral Medications
• Narcotic Medications
• Anti-Inflammatory Medications
• Antihistamines
• Anticonvulsants
• Capsaicin
• Numbing Creams, Gels, or Patches
• Vaccines
• Others

Global Herpes Zoster Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Others

Global Herpes Zoster Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Research & Academic Institutes
• Home Care Settings
• Others

Global Herpes Zoster Therapeutics Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ModernaTX, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luzhu Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EpiVax (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WEX Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations